Therapy targeting β-cell survival and function in type 2 diabetes mellitus

Type 2 diabetes is associated with both insulin resistance and impaired insulin secretion at diagnosis. As the disease progresses, insulin secretion is gradually decreased. Evidently, loss of insulin secretion per se, may cause diabetes, as in type 1 diabetes and LADA, but more importantly, the sing...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes research and clinical practice 2006-11, Vol.74 (2), p.S63-S69
Main Author: Porksen, Niels
Format: Article
Language:English
Subjects:
Insulin secretion
Progressive disease
Type 2 diabetes
β-cell
β-cell mass
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Type 2 diabetes is associated with both insulin resistance and impaired insulin secretion at diagnosis. As the disease progresses, insulin secretion is gradually decreased. Evidently, loss of insulin secretion per se, may cause diabetes, as in type 1 diabetes and LADA, but more importantly, the single gene defects associated with MODY are all related to the β-cell: for MODY 2 it is glucokinase, and for 1, 3, 4 and 5 it is transcription factors associated with proliferation and/or differentiation of β-cells. In contrast, severe insulin resistance, as in obesity, only causes diabetes in a minority of subjects, and in those developing diabetes, impaired insulin secretion is present. The loss of insulin secretion may be attributed to loss of function in individual cells, loss of β-cell mass, or a combination hereof. Therefore, it seems crucial to target the deterioration of insulin secretion, as a key factor to address diabetes progression.
ISSN:0168-8227
1872-8227
DOI:10.1016/j.diabres.2006.06.014